Viking Therapeutics (VKTX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
March 7, 2018 4:05 PM ESTSAN DIEGO, March 7, 2018 /PRNewswire/ --Â Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2017, and provided an update on its clinical pipeline and other corporate developments.
Highlights from, and Subsequent to, the Quarter Ended December 31, 2017
"The last year has been transformative for Viking as we announced positive clinical data for our lead program, VK5211 for hip fracture, advanced our Phase 2 clinical trial... More
